Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Operating Leases (2023 - 2025)

bioAffinity Technologies (BIAF) has disclosed Operating Leases for 3 consecutive years, with $202878.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 56.8% to $202878.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $202878.0 through Dec 2025, down 56.8% year-over-year, with the annual reading at $202878.0 for FY2025, 56.8% down from the prior year.
  • Operating Leases for Q4 2025 was $202878.0 at bioAffinity Technologies, down from $375139.0 in the prior quarter.
  • The five-year high for Operating Leases was $469596.0 in Q4 2024, with the low at $202878.0 in Q4 2025.
  • Average Operating Leases over 3 years is $350289.2, with a median of $364940.0 recorded in 2024.
  • The sharpest move saw Operating Leases soared 65.93% in 2024, then tumbled 56.8% in 2025.
  • Over 3 years, Operating Leases stood at $283001.0 in 2023, then skyrocketed by 65.93% to $469596.0 in 2024, then crashed by 56.8% to $202878.0 in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $202878.0, $375139.0, and $274074.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.